Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025

  • ID: 4085092
  • Report
  • Region: Global
  • 168 pages
  • P&S Market Research
1 of 4
Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors are the therapeutic candidates or drugs, popularly known as checkpoint inhibitors, used most commonly for the treatment of cancer and other malignancies. Programmed death 1 (PD-1) is found on the surface of cancer cells and it is used by tumor cells to evade the immune system. PD-1 inhibitors block the action of PD-1 receptor, enable the body to attack and kill cancer cells. It can constantly monitor body for abnormal cells, and eliminate them before they can turn into cancer. The tumor development process tries to find its way in shutting down the activation of immune system. After the activation of T cells, a stop signal is needed to make sure it does not get over-activated. This can be done through inhibitory receptors, such as PD-1.

PD1 and PDL1 Inhibitors Pipeline Analysis

PD-1 proteins bind with two ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). PD-L1 in humans is encoded by the CD274 gene. PD-L1 is a 40kDa type 1 transmembrane protein that contains CD274 gene. PD-L1 inhibitors plays a key role in suppressing the immune system during tissue allograft, pregnancy, autoimmune disease, hepatitis and other diseases.

The PD-1 and PD-L1 inhibitors market is expected to grow at a CAGR of 23.4% during 2017 - 2025. The increased investment and funding, strong pipeline, technological advancements and innovations, high prevalence of cancer, and improved safety and efficacy are the key factors driving the growth of global market. Different companies are developing PD-1 and PD-L1 inhibitor drugs by using innovative techniques such as combination therapy and biomarkers. In combination therapy approach, PD-1 and PD-L1 inhibitors combine with all types of molecules such as monoclonal antibodies, vaccines, small molecule and cell therapies. The two therapies given together are more effective and powerful as compared to single immunotherapy. This will significantly drive the growth of the global PD-1 and PD-L1 inhibitors market.

The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs in different stages of development and there are approximately 245 active clinical studies.

The increased use of combination therapy of PD-1 and PD-L1 inhibitors represent a new signal of immunotherapeutic, which is expected to alter the standard of care for cancer across the globe.

Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc and others.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Research Scope And Methodology
1.1 Market Definition
1.2 Research Scope
1.2.1 Market Segmentation By Drug
1.2.2 Market Segmentation By Mechanism Of Action (Moa)
1.3 Research Methodology And Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Market Outlook
3.1 Introduction
3.2 Trends In The Global Pd-1 & Pd-L1 Inhibitors Market
3.3 Opportunities In The Global Pd-1 & Pd-L1 Inhibitor Market
3.4 Factors Driving Growth Of The Market And Its Impact On Market Forecast
3.5 Factors Hindering The Growth Of The Market And Its Impact On Market Forecast

4. Global Pd-1 & Pd-L1 Inhibitors Pipeline Analysis
4.1 Overview
4.4.1 Pipeline Analysis By Moa
4.4.2 Pipeline Analysis By Molecule Type
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Global Pd-1 & Pd-L1 Inhibitors Pipeline Analysis By Phase (2016)
5.1 Filed: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Iii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase Ii: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug Profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Strategic Development
5.5.4 Designation
5.5.5 Grants
5.5.6 Patent
5.5.7 Technology

6 Competitive Landscape
6.1 Swot Analysis Of Pd-1 And Pd-L1 Inhibitors

7 Global Pd-1 & Pd-L1 Inhibitors Market Size And Forecast (2015 - 2025)
7.1 Global Pd-1 & Pd-L1 Inhibitors Market, By Drug
7.2 Global Pd-1 & Pd-L1 Inhibitors Market, By Mechanism Of Action (Moa)

8 Global Pd-1 & Pd-L1 Inhibitors Market, By Drug
8.1 Opdivo (Nivolumab) Market
8.2 Keytruda (Pembrolizumab) Market
8.3 Tecentriq (Atezolizumab) Market
8.4 Durvalumab Market
8.5 Avelumab Market

9. Global Pd-1 & Pd-L1 Inhibitors Market, By Mechanism Of Action (Moa)
9.1 Pd-1 Inhibitor Market
9.2 Pd-L1 Inhibitor Market

10. Competitive Analysis
10.1 Porter’S Five Forces Of Competitive Position Analysis
10.2 Market Share Analysis Of Key Players

11. Company Profiles And Strategic Developments

12. Appendix

List Of Tables
Specific Primary And Secondary Sources Used For This Publication
Global Pd-1 & Pd-L1 Inhibitors Market Snapshot
Anti-Pd-1 Combinations With Monoclonal Antibodies Or Other Immuno-Oncology Agents
Anti-Pd-L1 Combinations With Monoclonal Antibodies Or Other Immuno-Oncology Agents
Anti Pd-1 & Pd-L1 Mab Combinations With Vaccines
Anti Pd-1 & Pd-L1 Mab Combined With Gene And Cell Therapies And Other Novel Approaches
Different Drug Designation For Pd-1 & Pd-L1 Inhibitors
Drivers For The Market: Impact Analysis
Restraints For The Market: Impact Analysis
Pipeline Analysis Of Pd-1 & Pd-L1 Inhibitors, By Company (2016)
Description Of Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Swot Analysis Of Bace Inhibitors Pipeline
Global Pd-1 & Pd-L1 Inhibitors Market, By Drug, $M (2014-2016)
Global Pd-1 & Pd-L1 Inhibitors Market, By Drug, $M (2017-2025)
Global Pd-1 & Pd-L1 Inhibitors Market, By Moa, $M (2014-2016)
Global Pd-1 & Pd-L1 Inhibitors Market, By Moa, $M (2017-2025)
Global Opdivo Market, By Country, $M (2014-2016)
Global Opdivo Market, By Country, $M (2017-2025)
Companies- At A Glance

List Of Figures
Research Scope For Global Pd-1 & Pd-L1 Inhibitors Market
Research Methodology For Global Pd-1 & Pd-L1 Inhibitors Market
Deactivated T Cell In Pd-1 And Pd-L1
Activated T Cell In Pd-1 And Pd-L1 Inhibitors
Global Deaths Caused By Cancer (2012)
Number Of Products Under Development For Pd-1 And Pd-L1 Inhibitors (2016)
Global Pd-1 And Pd-L1 Inhibitors Pipeline Split, By Mechanism Of Action (2016)
Global Pd-1 And Pd-L1 Inhibitors Pipeline Split, By Molecule Type (2016)
Global Pd-1 And Pd-L1 Inhibitors Pipeline Split, By Route Of Administration (2016)
Global Pd-1 & Pd-L1 Inhibitors Market, $M (2014-2025)
Global Pd-1 & Pd-L1 Inhibitors Market, By Drug, $M (2014-2025)
Global Pd-1 & Pd-L1 Inhibitors Market Split, By Drug (2016)
Global Pd-1 & Pd-L1 Inhibitors Market, By Moa, $M (2014-2025)
Global Pd-1 & Pd-L1 Inhibitors Market Split, By Moa (2016)
Global Opdivo Market, $M (2014-2025)
Global Opdivo Market, By Country, $M (2014-2025)
Global Opdivo Market Split, By Country (2016)
Global Keytruda Market, $M (2014-2025)
Global Tecentriq Market, $M (2014-2025)
Global Durvalumab Market, $M (2014-2025)
Global Avelumab Market, $M (2014-2025)
Global Pd-1 Inhibitor Market, $M (2014-2025)
Global Pd-L1 Inhibitor Market, $M (2014-2025)
Porter’S Five Forces Of Competitive Position Analysis
Market Share Analysis Of Key Players (2016)
Market Share Analysis Of Key Players (2025)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll